FP
Flagship Pioneering Portfolio holdings
AUM
$268M
This Quarter Return
+94.37%
1 Year Return
-54.4%
3 Year Return
-51.2%
5 Year Return
+66.7%
10 Year Return
–
AUM
$3.62B
AUM Growth
+$3.62B
(+5.2%)
Cap. Flow
-$708M
Cap. Flow
% of AUM
-19.57%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
8
New
–
Increased
–
Reduced
2
Closed
–
Top Buys
No buys this quarter
Top Sells
| 1 |
Moderna
MRNA
|
$637M |
| 2 |
Denali Therapeutics
DNLI
|
$71.7M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Moderna
MRNA
$9.37B
| $2.18B | 60.34% | 30,871,524 -9,000,000 | -23% | -$637M |
|
2
Seres Therapeutics
MCRB
$166M
| $611M | 16.87% | 21,571,764 | – | – |
|
|
KLDO
3
DELISTED
Kaleido Biosciences, Inc. Common Stock
KLDO
| $214M | 5.92% | 19,360,710 | – | – |
|
|
4
Denali Therapeutics
DNLI
$2.23B
| $214M | 5.92% | 5,980,263 -2,000,000 | -25% | -$71.7M |
|
|
RUBY
5
DELISTED
Rubius Therapeutics, Inc
RUBY
| $192M | 5.3% | 38,296,526 | – | – |
|
|
EVLO
6
DELISTED
Evelo Biosciences, Inc. Common Stock
EVLO
| $121M | 3.33% | 22,900,069 | – | – |
|
|
AXLA
7
DELISTED
Axcella Health Inc. Common Stock
AXLA
| $58M | 1.6% | 12,548,414 | – | – |
|
|
SYRS
8
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $26M | 0.72% | 2,938,494 | – | – |
|